# New Onset Type 1 Diabetes: Role of Exenatide

> **NCT01269034** · PHASE4 · COMPLETED · sponsor: **Albert Einstein College of Medicine** · enrollment: 13 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Exenatide
- **DRUG:** Rapid and long acting insulin
- **DRUG:** long acting insulin + rapid acting + 1.25 mcg Exenatide

## Key facts

- **NCT ID:** NCT01269034
- **Lead sponsor:** Albert Einstein College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2017-01-31
- **Final completion:** 2017-01-31
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2021-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01269034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01269034, "New Onset Type 1 Diabetes: Role of Exenatide". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01269034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*